ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$9.79 USD
-0.14 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.98 +0.19 (1.94%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SPRY 9.79 -0.14(-1.41%)
Will SPRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for SPRY
Is SPRY gaining bearish strength? 1,2,3 Retracement Bearish shows up after slipping 1.41%
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) Gains on Japanese Approval for Neffy Nasal Spray
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
SPRY Gains Approval in Japan for Needle-Free Allergy Treatment